BR9612574A - Vetores virais de replicação condicional e seu uso - Google Patents

Vetores virais de replicação condicional e seu uso

Info

Publication number
BR9612574A
BR9612574A BR9612574-8A BR9612574A BR9612574A BR 9612574 A BR9612574 A BR 9612574A BR 9612574 A BR9612574 A BR 9612574A BR 9612574 A BR9612574 A BR 9612574A
Authority
BR
Brazil
Prior art keywords
viral
conditional replication
vectors
vector
host cell
Prior art date
Application number
BR9612574-8A
Other languages
English (en)
Inventor
Boro Dropulic
Paula M Pitha
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of BR9612574A publication Critical patent/BR9612574A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

<B>VETORES VIRAIS DE REPLICAçãO CONDICIONAL E SEU USO<D> A presente invenção fornece um vetor viral de replicação condicional, processos de fabricação, modificação, propagação e acondicionamento seletivo, e o uso do citado vetor, moléculas isoladas de seq³ências de aminoácido e nucleotídeo especificadas relevantes aos citados vetores, uma composição farmacêutico e uma célula hospedeira compreendendo tal vetor, o uso de uma citada célula hospedeira para seleção de drogas. Os processos incluem o tratamento profilático e terapêutico de infecção viral, em particular infecção por HIV, e desse modo, também são dirigidos a vacinas virais e ao tratamento de câncer, em particular câncer de etiologia viral. Outros processos incluem o uso dos citados vetores virais de replicação condicional em terapia de gene e outras aplicações.
BR9612574-8A 1995-11-28 1996-11-27 Vetores virais de replicação condicional e seu uso BR9612574A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56345995A 1995-11-28 1995-11-28
PCT/US1996/018997 WO1997020060A1 (en) 1995-11-28 1996-11-27 Conditionally replicating viral vectors and their use

Publications (1)

Publication Number Publication Date
BR9612574A true BR9612574A (pt) 2000-04-25

Family

ID=24250568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9612574-8A BR9612574A (pt) 1995-11-28 1996-11-27 Vetores virais de replicação condicional e seu uso

Country Status (19)

Country Link
EP (2) EP0871757B1 (pt)
JP (2) JP2000503527A (pt)
KR (1) KR100537458B1 (pt)
CN (3) CN1651577A (pt)
AT (2) ATE455858T1 (pt)
AU (3) AU1124997A (pt)
BR (1) BR9612574A (pt)
CA (1) CA2236868C (pt)
CZ (1) CZ294170B6 (pt)
DE (2) DE69626681T2 (pt)
DK (1) DK0871757T3 (pt)
ES (1) ES2188802T3 (pt)
HK (1) HK1060152A1 (pt)
IL (2) IL124636A0 (pt)
NO (1) NO329619B1 (pt)
NZ (1) NZ324157A (pt)
PT (1) PT871757E (pt)
RU (1) RU2270250C2 (pt)
WO (1) WO1997020060A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030742A1 (en) * 1997-12-12 1999-06-24 Luigi Naldini Therapeutic use of lentiviral vectors
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
EP1356070A2 (en) * 2000-09-22 2003-10-29 Virxsys Conditionally replicating viral vectors and their use
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
DK2222861T3 (en) 2007-12-11 2018-02-05 Univ North Carolina Chapel Hill POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS
TR201903651T4 (tr) * 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
KR20230109773A (ko) * 2015-02-24 2023-07-20 바이오아트라, 인코퍼레이티드 조건부 활성 생체 단백질
CN104711294A (zh) * 2015-04-02 2015-06-17 扬州大学 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
GB2543730A (en) * 2015-05-26 2017-05-03 Andrzejewski Slawomir Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1994026877A1 (en) * 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
DE69534864T2 (de) * 1994-01-05 2007-02-22 Gene Shears Pty. Ltd. Ribozyme gegen eine HIV Tat Sequenz
EP0759471A4 (en) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof

Also Published As

Publication number Publication date
JP2007014341A (ja) 2007-01-25
ATE455858T1 (de) 2010-02-15
CA2236868C (en) 2014-01-21
JP4384146B2 (ja) 2009-12-16
CN1651577A (zh) 2005-08-10
IL124636A (en) 2009-12-24
HK1060152A1 (en) 2004-07-30
AU767620B2 (en) 2003-11-20
NO982418L (no) 1998-07-27
JP2000503527A (ja) 2000-03-28
AU2004200663A1 (en) 2004-04-08
EP1380650B1 (en) 2010-01-20
DE69626681T2 (de) 2004-02-12
NO329619B1 (no) 2010-11-22
CZ162498A3 (cs) 1998-12-16
WO1997020060A1 (en) 1997-06-05
DK0871757T3 (da) 2003-07-14
AU1000001A (en) 2001-05-17
CZ294170B6 (cs) 2004-10-13
CA2236868A1 (en) 1997-06-05
ATE234362T1 (de) 2003-03-15
PT871757E (pt) 2003-08-29
KR100537458B1 (ko) 2008-09-08
KR19990071728A (ko) 1999-09-27
RU2270250C2 (ru) 2006-02-20
CN1940076A (zh) 2007-04-04
CN1207775A (zh) 1999-02-10
CN100390291C (zh) 2008-05-28
ES2188802T3 (es) 2003-07-01
IL124636A0 (en) 1998-12-06
EP0871757B1 (en) 2003-03-12
AU2004200663B2 (en) 2007-07-05
EP1380650A1 (en) 2004-01-14
AU1124997A (en) 1998-06-19
DE69626681D1 (de) 2003-04-17
EP0871757A1 (en) 1998-10-21
NO982418D0 (no) 1998-05-27
NZ324157A (en) 2000-10-27
DE69638120D1 (de) 2010-03-11

Similar Documents

Publication Publication Date Title
HU et al. 2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo
BR9612574A (pt) Vetores virais de replicação condicional e seu uso
AU2024202093A1 (en) Peptides and nanoparticles for intracellular delivery of mrna
Kurilla et al. Rapid and transient localization of the leader RNA of vesicular stomatitis virus in the nuclei of infected cells.
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
Knap et al. Protection from chemical modification of nucleotides in complexes of M1 RNA, the catalytic subunit of RNase P from E coli, and tRNA precursors
Havron et al. Specificity of photochemical crosslinking in protein-nucleic acid complexes: identification of the interacting residues in RNase-pyrimidine nucleotide complex
Stetor et al. Characterization of (+) strand initiation and termination sequences located at the center of the equine infectious anemia virus genome
EP0977862B8 (en) Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
Tyc et al. Multiple ribosome binding to the 5′‐terminal leader sequence of tobacco mosaic virus RNA: Assembly of an 80S ribosome· mRNA complex at the AUU codon
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
Thiele et al. Separation and sequence of the 3′ termini of M double-stranded RNA from killer yeast
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
Van Duin et al. Functional Recognition of Phage RNA by 30‐S Ribosomal Subunits in the Absence of Initiator tRNA
Takahashi et al. Activation of Ada protein as a transcriptional regulator by direct alkylation with methylating agents.
Litman et al. Evidence for a conformational change in the 30 S E. coli ribosomal subunit upon formation of 70 S particles
BR0211178A (pt) Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico
KR950701345A (ko) 엘라스타제 저해활성을 갖는 신규 펩티드 및 그의 제조방법
WO1992004903A1 (en) Method of inhibiting viral production
Mushinski Hepatoma—foetal Phe-tRNA also present in normal rat liver
Rose Ribosome recognition and translation of vesicular stomatitis virus messenger RNA
Yamaki et al. Inhibition of SV40 DNA replication invitro by 1-N-acyl-3 ″-N-(trifluoroacetyl) kanamycin
Stringfellow Chemotherapy of viral infections

Legal Events

Date Code Title Description
FD5 Application fees: dismissal - article 86 of industrial property law
HIX Notification cancelled
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART 8O COMBINADO COM ART. 13 DA LPI), NAO E CONSIDERADO INVENCAO, POR INCIDIR NO ART. 10 (IX) E (VIII), PELAS REIVINDICACOES ESTAREM INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI), POR NAO SE REFERIR A UMA UNICA UNIDADE DE INVENCAO (ART. 22) E COM BASE NO ART. 229 DA LEI 9.279/96, SEGUNDO REDACAO DADA PELO ARTIGO 229-A DA LEI 10.196/01.

B12B Appeal against refusal [chapter 12.2 patent gazette]